Global Pleurodynia Treatment Market Is Predicted to Grow Around USD 191.58 Million By 2030

The global pleurodynia treatment market size was worth around USD 128.57 Million in 2022 and is predicted to grow to around USD 191.58 Million by 2030 with a compound annual growth rate (CAGR) of roughly 5.28% between 2023 and 2030.

The pleurodynia treatment industry revolves around the production and use of drugs, therapies, and other treatment options that are used to manage the symptoms of pleurodynia which is also known as Bornholm disease. The condition is characterized by symptoms like fever, severe chest & abdominal pain, and muscle stiffness. It is caused by enteroviruses, such as Echovirus and Coxsackievirus B. Studies have shown that pleurodynia is self-restricted which means that it will cure on its own after some time.

However, cases with severe symptoms require additional medical care. Currently, the healthcare sector does not have any accurate cure for the condition since there are no US Food & Drugs Administration (FDA)-approved drugs for the treatment. However, several antiviral drugs and other therapies may be used to manage the symptoms of the condition. The industry revolves around companies and organizations involved in the development, production, and distribution of these treatments along with healthcare professionals.

The global pleurodynia treatment market is projected to grow owing to increasing awareness about the condition. The industry is relatively new and the symptoms of pleurodynia can be easily associated with other conditions since the symptoms are very common. However, the growing number of cases has led to the government and healthcare industry undertaking several initiatives targeting the generation of mass awareness related to the condition and the treatment methods that can be used. Furthermore, the healthcare sector is also investing in various research activities to understand the virus and develop novel drugs and therapies that can provide accurate care.

The pleurodynia treatment industry may also benefit from the overall growing investments in healthcare infrastructure witnessed across the globe. Countries are investing in deploying more effective treatment solutions due to increased pressure caused by growing expectations and demand from patients for adequate care. In addition to this, advances in technology are expected to drive the development of new treatments for pleurodynia. For instance, the use of artificial intelligence and machine learning could help to identify new drug targets and develop more effective treatments.

One of the key drawbacks in the industry is the availability of only limited treatment options. Currently, there are no remedies for treating the condition from its root. The medicines available in the pleurodynia treatment market only assist in managing the associated symptoms or pain relief. The patient may have to deal with the condition on their own and wait for it to subside in case of an absolute lack of access to medical care. This is further affected by the lack of adequate awareness amongst the population and healthcare professionals, especially in emerging economies.

The growing investment toward novel therapies may prove growth opportunities while the regulatory challenges could restrict market expansion.

The global pleurodynia treatment market is segmented based on causes, complications, symptoms, and region.

Based on causes, the global market segments are Coxsackievirus B, Coxsackievirus A, and echovirus. In 2022, the industry witnessed the highest growth in the Coxsackievirus B segment since it is considered the largest cause of the condition. Various studies have indicated that more than 90% of the cases of pleurodynia are caused by Coxsackievirus B while the rest of the two reasons remain relatively low in terms of leading cause. The virus is a member of the enterovirus family and exists alongside Coxsackievirus A and Echovirus. It can be easily transmitted through close contact with an infected patient or from contaminated food or water, and surfaces. The infected patient may suffer from various symptoms including fever, headache, muscle aches, and respiratory concerns.

Based on complications, the pleurodynia treatment industry divisions are meningitis, tachycardia, hepatitis, pericarditis, myocarditis, and orchitis. In 2022, the industry witnessed the highest growth in the pericarditis and myocarditis segments. The former refers to the inflammation of the heart-surrounding sac whereas the latter is the inflammation of the heart muscle itself. The complications include symptoms like chest pain and heart failure and can be serious if not handled with precaution. The rest of the complications like meningitis, tachycardia, hepatitis, and orchitis are not very common but it is important to note that every patient's case history is different from the rest.

Based on symptoms, the global market divisions are chest pain, cough, fever, sore throat, headache, and muscular aches & pain.

North America is anticipated to lead the global pleurodynia treatment market due to the high incidence rate of the condition and the presence of well-established healthcare infrastructure. In addition to this, the increasing investment in R&D activities and the presence of major pharmaceutical companies in the region are expected to drive regional market growth. Europe is also expected to be a significant market for pleurodynia treatment due to the increasing prevalence of the condition in the region.

The presence of favorable government policies and reimbursement schemes, as well as the increasing investment in healthcare infrastructure. Growth in Asia-Pacific may be driven due to the presence of a large patient pool, increasing healthcare spending, and the rising adoption of advanced healthcare technologies.

This review is based on a report by Zion Market Research, titled “Pleurodynia Treatment Market By Causes (Coxsackievirus B, Coxsackievirus A, and Echovirus), By Complications (Meningitis, Tachycardia, Hepatitis, Pericarditis, Myocarditis, and Orchitis)), By Symptoms (Chest Pain, Cough, Fever, Sore Throat, Headache, and Muscular Aches & Pains), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2023 – 2030.”- Report at https://www.zionmarketresearch.com/report/pleurodynia-treatment-market

.Recent Developments:

• In January 2023, verywellhealth, an online award-winning site that provides fact-based and credible information on various aspects of health-related conditions, claimed that although there is no specific treatment for the condition, patients can use nonsteroidal anti-inflammatory drugs like ibuprofen (Advil) to reduce pleurodynia-related pain. They also suggested that the application of warm packs on the affected area may also help relieve pain
• In April 2022, a study published on the Frontiers site claimed that ethyl 3-hydroxy hexanoate (EHX) which is a volatile compound found in food additives and fruits can be a potential compound working against Coxsackievirus B infections. The study also suggested that the use of EHX can be considered a safe therapeutic option during the treatment process

The global pleurodynia treatment market is led by players like:

• Roche Holding AG
• Gilead Sciences
• AbbVie
• GlaxoSmithKline
• Bristol Myers Squibb
• Johnson & Johnson
• Boehringer Ingelheim
• Pfizer
• Novartis
• Takeda Pharmaceuticals
• Merck & Co.
• Bayer
• Teva Pharmaceutical Industries
• AstraZeneca
• Amgen
• Eli Lilly and Company
• Sanofi
• Daiichi Sankyo
• Astellas Pharma.

The global pleurodynia treatment market is segmented as follows:

By Causes

• Coxsackievirus B
• Coxsackievirus A
• Echovirus

By Complications

• Meningitis
• Tachycardia
• Hepatitis
• Pericarditis
• Myocarditis
• Orchitis

By Symptoms

• Chest Pain
• Cough
• Fever
• Sore Throat
• Headache
• Muscular Aches & Pains

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com